Top Story Today
Wave's Obesity Drug Killed Visceral Fat but Barely Moved the Scale. The Stock Paid the Price.
Wave Life Sciences shares cratered roughly 50% in a single day after its obesity candidate WVE-007 showed just 0.9% body weight loss at the 400 mg dose over three months. The cruel irony: the drug actually produced a 14% reduction in visceral fat and a 2% gain in lean muscle, the opposite of what GLP-1 drugs typically do. But in a market where Wegovy delivers 15%+ weight loss and Lilly's retatrutide has hit 28.7%, anything under the FDA's 5% threshold reads like a death sentence.
Why it matters: The obesity drug race has become a one-metric contest: the number on the scale. Until the field evolves to value body composition alongside raw weight loss, biotechs with differentiated approaches will keep getting punished by a market that only speaks GLP-1.
Read more →Science & Discovery
Cancer-Killing Eye Drops Made From Pig Semen Actually Worked in Mice
No FDA-approved eye drop exists for any type of eye cancer, which makes this study in Science Advances worth paying attention to despite the bizarre sourcing. A Chinese research team extracted exosomes (tiny lipid-coated delivery vehicles) from boar semen, loaded them with cancer-fighting nanoparticles, and used them as eye drops that killed retinoblastoma cells in mice while preserving healthy retinal tissue. The logic: sperm exosomes evolved to cross biological barriers, and the eye has plenty of those.
Read more →